Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INTELLIA THERAPEUTICS, INC.

(NTLA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
111.73(c) 115.01(c) 106.92(c) 109.95(c) 101.03(c) Last
605 763 888 848 958 916 823 775 979 117 Volume
-1.24% +2.94% -7.03% +2.83% -8.11% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 29,6 M - -
Net income 2021 -250 M - -
Net cash position 2021 882 M - -
P/E ratio 2021 -28,3x
Yield 2021 -
Sales 2022 41,0 M - -
Net income 2022 -292 M - -
Net cash position 2022 576 M - -
P/E ratio 2022 -25,6x
Yield 2022 -
Capitalization 7 519 M 7 519 M -
EV / Sales 2021 224x
EV / Sales 2022 169x
Nbr of Employees 312
Free-Float 90,0%
More Financials
Company
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing potentially curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated 9 (Cas9) technology. The Company's CRISPR/Cas9 is a technology for genome editing, process of altering selected sequences of genomic deoxyribonucleic acid (DNA). To fully realize the... 
Sector
Biotechnology & Medical Research
Calendar
12/11 | 05:30pmPresentation
More about the company
Ratings of Intellia Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about INTELLIA THERAPEUTICS, INC.
11/22Intellia Therapeutics Expands Phase 1 Study of NTLA-2001 to Patients With Transthyretin..
MT
11/22Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Studyáof NTLA-2001 to Incl..
AQ
11/22Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Incl..
CI
11/18Novartis Said Considering Takeover in Biotech Sector
MT
11/08Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing..
AQ
11/05HC Wainwright Adjusts Intellia Therapeutics' Price Target to $182 from $171, Keeps Buy ..
MT
11/05Oppenheimer Adjusts Intellia Therapeutics PT to $145 From $160, Maintains Perform Ratin..
MT
11/05Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing..
GL
11/05Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing..
GL
11/04INTELLIA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
11/04Wedbush Adjusts Price Target for Intellia Therapeutics to $137 From $130, Maintains Neu..
MT
11/04Intellia Therapeutics Widens Loss in Q3, Revenue Drops
MT
11/04Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Rec..
PU
11/04Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Rec..
GL
11/04Intellia Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Mon..
CI
More news
News in other languages on INTELLIA THERAPEUTICS, INC.
11/22Intellia Therapeutics étend l'étude de phase 1 du NTLA-2001 aux patients atteints d'amy..
11/18Novartis envisagerait une reprise dans le secteur des biotechnologies
11/04Intellia Therapeutics creuse sa perte au troisième trimestre et réduit son chiffre d'af..
10/20Intellia Therapeutics déclare que les données précliniques montrent des progrès dans le..
10/05Les actions d'Intellia Therapeutics augmentent après que Guggenheim ait initié une couv..
More news
Analyst Recommendations on INTELLIA THERAPEUTICS, INC.
More recommendations
Chart INTELLIA THERAPEUTICS, INC.
Duration : Period :
Intellia Therapeutics, Inc. Technical Analysis Chart | NTLA | US45826J1051 | MarketScreener
Technical analysis trends INTELLIA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 101,03 $
Average target price 174,56 $
Spread / Average Target 72,8%
EPS Revisions
Managers and Directors
John M. Leonard President, Chief Executive Officer & Director
Glenn Goddard Executive VP, Chief Financial & Accounting Officer
Frank A. G. M. Verwiel Chairman
Laura Sepp-Lorenzino Chief Scientific Officer & Executive VP
Eliana Clark Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
INTELLIA THERAPEUTICS, INC.96.54%7 519
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298